Influence of Thoracic Paravertebral Block on Cardiac Repolarization

Sponsor
Medical University of Gdansk (Other)
Overall Status
Enrolling by invitation
CT.gov ID
NCT05822076
Collaborator
(none)
60
1
15.9
3.8

Study Details

Study Description

Brief Summary

Aim of the study is to determine the presence and direction of electrocardiographical changes of cardiac repolarization after thoracic paravertebral block, depending on block laterality.

Injection of local anaesthetic into paravertebral space (paravertebral block, PVB) temporarily impairs transmission in nerve fibers in proximity of the deposition site. In case of PVB covering the rami of upper thoracic spinal nerves, among the others thoracic sympathetic cardiac nerves are blocked, possibly affecting action potential time of heart, especially the repolarization, and the related electrocardiographic phenomena.

The risk of life-threatening polymorphic ventricular tachycardia (torsade des pointes, TdP) is associated with certain electrocardiographical symptoms, like QT interval prolongation and increased transmural repolarization dispersion (TDR). Determining the presence and direction of cardiac repolarization changes after a thoracic PVB will allow to conclude about its impact on TdP risk: protective or, contrary, arrhythmogenic.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Paravertebral block (ropivacaine) left
  • Procedure: Paravertebral block (ropivacaine) right

Detailed Description

After obtaining written informed consent, 60 women above 18 years of age scheduled to elective breast surgery in combined regional and general anaesthesia will be enrolled to study, divided in two groups depending of the side of operation. Participants will undergo the ultrasound-guided paravertebral block with single injection of 0.5% ropivacaine (0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients) without adjuvants. Before injection (T0) and after confirmation of sufficient sensory block area covering 1st to 4th thoracic dermatomes (T1), 12-lead electrocardiogram (ECG) will be recorded using a Holter device. First examination of sensory block distribution will be performed 6 minutes after injection, with subsequent examinations if needed - every minute up to 15 minutes. No sedative premedication, general anaesthesia induction or additional medications (except of neutral saline maintaining intravenous access) will be administered until completions of ECG recording. Both T0 and T1 electrocardiogram will be preceded by rest in supine position for at least 5 minutes, without any medical procedures other than monitoring. Cases with baseline QT or corrected QT longer than 440 milliseconds (ms) will be excluded from study.

The QT interval and TDR (measured as time in milliseconds between ECG T wave peak [Tpeak] and end [Tend]) values obtained from baseline and post-blockade electrocardiograms will be statistically analyzed and compared between study groups.

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Evaluation of Influence of Thoracic Paravertebral Block on Cardiac Repolarization
Actual Study Start Date :
Feb 2, 2023
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
L - paravertebral block left

30 woman above 18 years of age qualified for elective breast surgery on the left side of the body

Procedure: Paravertebral block (ropivacaine) left
Paravertebral block at the level of 3rd thoracic intervertebral space on the left side. Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients

P - paravertebral block right

30 woman above 18 years of age qualified for elective breast surgery on the right side of the body

Procedure: Paravertebral block (ropivacaine) right
Paravertebral block at the level of 3rd thoracic intervertebral space on the right side. Ropivacaine 0.3 ml·kg-1, not exceeding 30 ml, based on ideal body weight in obese patients

Outcome Measures

Primary Outcome Measures

  1. QT interval [during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))]

    difference in milliseconds of QT interval between baseline ECG [T0] and ECG after confirmation of sufficient area of sensory block [T1]

  2. Corrected QT interval [during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))]

    difference in milliseconds of QT interval corrected [according to Bazett, Framingham, Fredericia formulas] between baseline ECG [T0] and ECG after confirmation of sufficient area of sensory block [T1]

  3. Tpeak-Tend [during procedure (6 minutes (prolonged until sufficient block distribution is achieved up to 15 minutes))]

    difference in milliseconds of Tpeak-Tend time between baseline ECG [T0] and ECG after confirmation of sufficient area of sensory block [T1]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • woman above 18 years of age, legally able of giving informed consent

  • participants previously qualified for elective breast surgery due to neoplasm, with or without axillary node dissection

  • physical status corresponding to class I or II in American Society of Anaesthesiologist classification

Exclusion Criteria:
  • lack of consent to participation or to regional anaesthesia for planned surgery

  • bilateral operation planned

  • symptomatic circulatory disease at the time of qualification, artificial heart pacemaker presence, positive history of arrythmia

  • allergy to amide local anaesthetics

  • use of medications with "known" or "possible" potential of QT prolongation, according to Arizona Center for Education and Research on Therapeutics [AZCERT] Inc. list, in 5 days preceding the intervention

  • severe deformation of thoracic spine

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medical University of Gdańsk - Departament of Anesthesiology and Intensive Care Gdańsk Poland 80-214

Sponsors and Collaborators

  • Medical University of Gdansk

Investigators

  • Principal Investigator: Radosław Owczuk, MD, PhD, Medical University of Gdańsk

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Radosław Owczuk, Clinical Professor, Head of Department of Anesthesiology and Intensive Care, Medical University of Gdansk
ClinicalTrials.gov Identifier:
NCT05822076
Other Study ID Numbers:
  • NKBBN/948/2022
First Posted:
Apr 20, 2023
Last Update Posted:
Apr 24, 2023
Last Verified:
Apr 1, 2023
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Radosław Owczuk, Clinical Professor, Head of Department of Anesthesiology and Intensive Care, Medical University of Gdansk
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 24, 2023